Articles by Valentina Guarneri, MD
93 monarchE: Primary Overall Survival Results of Adjuvant Abemaciclib + Endocrine Therapy for HR+/HER2−, High-Risk, Early Breast Cancer
ByStephen R.D. Johnston,Miguel Martin, MD, PhD,Joyce O’Shaughnessy, MD,Roberto Hegg,Sara M. Tolaney, MD, MPH,Valentina Guarneri, MD,Lucia Del Mastro,Mario Campone,Javier Cortés, MD,Hope S. Rugo, MD,Matthew P. Goetz, MD,Erika P. Hamilton, MD,Elzbieta Senkus,Laura Testa,Patrick Neven, MD, PhD,Jens Huober, MD,Ran Wei,Maria Munoz,Priya Rastogi, MD,Nadia Harbeck, MD, PhD,Victoria Jennifer Stefaniak (Non-Author Presenter) 
New Combinations With Epirubicin in Advanced Breast Cancer
ByPierfranco Conte, MD,Alessandra Gennari, MD,Elisabetta Landucci, MD,Valentina Guarneri, MD,Sara Donati, MD,Barbara Salvadori, MD,Carmelo Bengala, MD Several trials have shown that anthracyclines and taxanes can be combined to achieve response rates ranging from 70% to 90%, with complete responses ranging from 19% to 41%. In an attempt to increase the activity while
Epirubicin/Taxane Combinations in Breast Cancer: Experience From Several Italian Trials
ByPierfranco Conte, MD,Alessandra Gennari, MD,Valentina Guarneri, MD,Elisabetta Landucci, MD,Sara Donati, MD,Barbara Salvadori, MD,Carmelo Bengala, MD,Editta Baldini, MD Doxorubicin/paclitaxel (Taxol) combinations are very active in advanced breast cancer, with objective response rates up to 90%, but have shown a high incidence of cardiotoxicity. A phase I/II trial replacing